Two Over-Billion-Yuan Fundraisings Highlight More Than Seven Deals in China's Pharma Sector Last Week

　　【Pharmaceutical Network Industry DynamicsAccording to statistics, last week (February 26 - March 1), there were 7 financing and investment activities in China's pharmaceuticals and health sector, two of which exceeded 100 million yuan: Zhejiang Mingdu Intelligent Control Technology Co., Ltd. and Shanghai Guangsheng Pharmaceutical Co., Ltd.
 

　　Mingdu Intelligent Cloud: Announces Completion of Hundreds of Millions of Yuan in Series C Financing
 

Specifically, on February 29, Zhejiang Mingdu Intelligent Control Technology Co., Ltd. announced the completion of a C-round financing worth several hundred million yuan. This round of financing was led by Shenzhen Capital Group with additional investment from China Merchants Health. After completing the financing, Mingdu Intelligent Cloud will continue to deepen its strategic layout in the life sciences field and promote and accelerate the digital transformation of the pharmaceuticals industry.
 

Industry insiders point out that with the advancement of healthcare reform in China, the normalization of bulk procurement, and the development trend of globalization, the pharmaceutical industry needs to address challenges by accelerating product launches and reducing operational costs. This has also given rise to a pharmaceutical digitalization market worth hundreds of billions. However, the digital transformation of China's local pharmaceutical companies is still in its early stages. Most pharmaceutical companies are at Industry 2.0 level, and the digital and information infrastructure of the pharmaceutical industry remains weak, indicating significant room for improvement in market penetration.
 

Data shows that Mingdu Intelligent Cloud is a digital transformation service provider in the life sciences field. The company has built a smart technology platform with "digital laboratories" and "digital factories" working in synergy, helping pharmaceutical companies achieve comprehensive digital transformation in digital R&D, production, future factories, and quality control.
 

　　Shanghai Guangsheng Pharmaceutical Co., Ltd.: Announces Completion of Over 100 Million RMB Series A Financing
 

Shanghai Guangsheng Pharmaceutical Co., Ltd. announced on February 28 that it had completed an A-round financing of over RMB 100 million invested by Oriental Fortune. The proceeds of this round of financing will be used to comprehensively accelerate the company's new product research and development in the field of photodynamic therapy and the commercialization of its first product.
 

It is reported that Shanghai Guangsheng Pharmaceutical Co., Ltd. is committed to promoting the development of excitation-based treatment methods such as photodynamic and sonodynamic therapies, mainly focusing on the research, development, production, and commercialization of innovative photosensitizers with independent intellectual property rights and related products.
 

Shanghai Guangsheng Pharmaceutical Co., Ltd. successfully purchased the 31-05 plot in the International Medical Park of Pudong New Area, with a total investment of approximately 410 million yuan. It is currently comprehensively constructing the Shanghai Guangsheng Pharmaceutical headquarters and R&D center, and the GMP factory is expected to be delivered for use in March 2024. At the same time, it will continue to build an innovation and incubation platform for light/sound dynamic related drugs and medical devices, promoting the innovative research and development of light/sound dynamic therapy in China for esophageal cancer, colorectal cancer, glioma, high-grade squamous intraepithelial lesion (HSIL), and other non-tumor fields.
 

In addition, the company will participate in new drug development projects of universities and research institutions both in China and abroad in various forms, and implement innovative achievements. Currently, the first proposed indication for Huaporphyrin Sodium is locally advanced or distantly metastatic esophageal cancer.
 

　　Pharmaceutical Company Plans to Raise Funds to Advance Innovative Drug R&D
 

Notably, last week also saw pharmaceutical companies planning to use financing funds to advance innovative drug research and development. For instance, StarMab BioMed announced on February 28th the completion of a multi-million RMB A+ round of financing. This round was jointly invested by Zhuhai Science and Technology Investment, Zhuhai High-Tech Investment, and Guangda Huitong, with Qidian Capital serving as the financial advisor for subsequent financing rounds. The proceeds will be used to promote the research and development of nano multi-antibody drugs, develop innovative multifunctional antibody drugs, and accelerate clinical R&D and commercialization processes.
 

Data shows that StarMab BioMed is an innovation-driven biopharmaceutical company dedicated to the discovery and development of novel drugs.
 

Currently, the company has developed a series of novel biopharmaceuticals with independent intellectual property rights. Several First-in-class multifunctional antibody biologics are undergoing early clinical trials in China and the United States. Among them, SM3321 has been granted IND approval in both China and the U.S. and has entered Phase I clinical trials. Preclinical data shows excellent anti-tumor efficacy and safety. Its structural design enables high-affinity targeting and binding to multiple tumor sites while activating immune cell functions, achieving specific killing of tumor cells while significantly reducing non-specific toxic reactions.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.